CPX
DAWN

Canaan Partners XI’s Day One Biopharmaceuticals DAWN Stock Holding History

Canaan Partners XI’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,491,561
Closed -$30.2M – 4
2023
Q3 		$30.6M Sell
2,491,561
-56,842
-2% -$741K 26.81% 2
2023
Q2 		$30.4M Hold
2,548,403
– – 21.55% 2
2023
Q1 		$34.1M Hold
2,548,403
– – 24.51% 2
2022
Q4 		$54.8M Sell
2,548,403
-4,415,898
-63% -$90.6M 43.06% 1
2022
Q3 		$139M Sell
6,964,301
-2,699,344
-28% -$57.4M 56.26% 1
2022
Q2 		$173M Hold
9,663,645
– – 61.6% 1
2022
Q1 		$95.9M Hold
9,663,645
– – 39.92% 1
2021
Q4 		$163M Buy
+9,663,645
New +$199M 41.94% 1

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Canaan Partners XI's DAWN Position: Q4 2023 in Review

Canaan Partners XI sold out of Day One Biopharmaceuticals (DAWN) in Q4 2023, closing a stake of 2,491,561 shares — an estimated $30.2M sold.

Canaan Partners XI first reported a position in DAWN in Q4 2021 and held it in 8 quarters. The position peaked at $173M in Q2 2022. 139 funds tracked by Wall St. Rank hold DAWN as of Q4 2023.

  • Canaan Partners XI reported no remaining Day One Biopharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Canaan Partners XI sold 2,491,561 Day One Biopharmaceuticals shares in Q4 2023, an estimated $30.2M.
  • Canaan Partners XI first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Canaan Partners XI's Day One Biopharmaceuticals position peaked at $173M in Q2 2022.
  • 139 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2023.

Based on Canaan Partners XI's 13F filing for Q4 2023, filed 1 Feb 2024.